bluechew zepbound tirzepatide partnership Zepbound™ (Tirzepatide) Richmond Charlottesville VA Zepbound (tirzepatide) FDA Approval History

In November 2024, Novo Nordisk AS is expected to secure expanded FDA approval for CagriSema, its dual amylin/GLP-1 agonist, for a broader population of patients with type 2 diabetes and high cardiovascular risk

You take multiple oral medications first thing in the morning

[PMID: 14017791] PubMed record related to this compound for laboratory literature review

Instruct patients using the single-dose vial of Mounjaro to use an appropriate syringe for administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL dose)

Unmatched Amplification: We've seen the data

Time savings: No need to work through complicated math